Ascentage Pharma Group International American Depository Shares (AAPG) vs Harrow (HROW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Harrow (HROW) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, losing 21.8% versus a loss of 60.9%. Harrow is the larger company by market cap ($1.14 billion vs $1.12 billion), about 1.0 times the size. Harrow converts more of its revenue into profit, with a net margin of -1.9% versus -41.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | HROW |
|---|---|---|
| Share price | $11.97 | $30.41 |
| Market cap | $1.12B | $1.14B |
| 1-day change | -3.78% | -5.35% |
| YTD return | -54.38% | -37.94% |
| 1-year return | -60.93% | -21.85% |
| 5-year return | — | +196.11% |
| Forward P/E | — | 16.26 |
| EPS (TTM) | $-2.26 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $134.35M | $272.30M |
| Revenue growth (YoY) | — | +36.41% |
| Net income (latest FY) | $-55.54M | $-5.14M |
| Gross margin | 97.03% | 75.05% |
| Operating margin | — | 11.21% |
| Net margin | -41.34% | -1.89% |
| 52-week high | $33.09 | $54.85 |
| 52-week low | $11.97 | $25.76 |
| Distance from 52-week high | -63.83% | -44.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +271.76% | +104.70% |
| Average volume | 6.97K | 626.20K |
| Shares outstanding | 93.33M | 37.53M |
| Employees | 828 | 373 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HROW has outperformed AAPG by 39.1 percentage points over the past year.
- Harrow is more profitable, keeping -1.9 cents of every revenue dollar as net income versus -41.3 cents for Ascentage Pharma Group International American Depository Shares.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
AAPG vs HROW FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Harrow?
Harrow (HROW) is larger, with a market capitalization of $1.14B compared with $1.12B for Ascentage Pharma Group International American Depository Shares (AAPG).
Which stock has performed better over the past year, AAPG or HROW?
HROW returned -21.85% over the past 12 months, compared with -60.93% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Harrow in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.